Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Condition: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Abemaciclib; Drug: Nivolumab; Procedure: Tumor biopsy; Procedure: Peripheral blood; Other: EORTC QLQ-30 Sponsors: Washington University School of Medicine; Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Chemotherapy | HNSCC | Skin Cancer | Squamous Cell Carcinoma